한글목차

세계의 빅터루비 시장 전망은 병원과 소매 약국 시장에서 기회가 있고 유망시되고 있습니다. 세계의 빅터루비 시장은 2025-2031년 CAGR 2.7%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 HIV 및 AIDS 유병률 증가, 계발 및 스크리닝 프로그램 증가, 단독 요법에 대한 기호 증가입니다.

• Lucintel의 예측에서는 유형별로는 제네릭 의약품이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 용도별로는 소매 약국이 높은 성장을 이룰 것으로 예측됩니다.
• 지역별로는 북미가 예측기간 동안 가장 높은 성장이 예상됩니다.

150페이지 이상의 종합적인 보고서를 통해 비즈니스 의사 결정에 도움이 되는 귀중한 인사이트를 얻을 수 있습니다.

빅터루비 시장의 새로운 동향

빅터 루비 시장은 견고하지만 불변하지는 않습니다. HIV 치료 환경 전반에서 미래의 방향과 위치를 형성하는 매우 중요한 동향이 많이 나타납니다. 이러한 추세에는 장기간 작용하는 주사제의 창출과 보급, 병존 질환을 가진 환자의 치료 중시 증가, 노출 전 예방제(PrEP)의 사용 확대, 단제 요법의 지속적인 관련성, 특허 만료과 제네릭 의약품의 경쟁에 의한 영향의 가능성 등이 포함됩니다. 미래 시장 동향을 예측하려면 이러한 동향에 대한 지식이 필수적입니다.

• 장시간 작용 주사 요법 : 카보테그라빌과 릴피비린(카베누바)을 포함한 장시간 작용 주사 항-레트로바이러스 요법의 개발과 사용 증가는 HIV 치료에서 큰 동향입니다. 이러한 치료법은 투여 횟수가 적은(예를 들어,월1회 또는 격월 1회) 이점을 제공하고, 정제의 부담을 최소화함으로써 환자의 복약 어드밴스 및 환자 만족도를 단순화할 수 있습니다. 빅터루비는 1일 1회 경구 투여라는 단순한 요법이지만, 투여 빈도가 더 적다는 매력은 일부 환자에게 매력적이며 장기적으로 빅터루비 시장 점유율에 영향을 줄 수 있습니다.
• 병존 질환을 가진 환자의 치료 중시 증가 : HIV 감염자는 종종 심혈관 질환, 신장 기능 장애, 뼈 건강 장애와 같은 합병증을 앓고 있습니다. 이 때문에 바이러스 억제 효과가 높을 뿐만 아니라 이러한 병존 질환을 고려한 안전하고 내약성이 높은 HIV 치료제가 필요합니다. 노인 환자와 병존 질환이 있는 환자의 빅터루비에 대한 장기 데이터는 현재 진행 중인 연구 및 임상시험에서 연구되고 있으며, 시장에서 이러한 복잡한 환자의 요구 사항을 충족시키는 중요성이 강조되고 있습니다.
• 사전 노출 예방 조치 확대 : 빅터루비 자체는 PrEP로 승인되지 않았지만, HIV 예방 요법에 대한 관심 증가와 PrEP 사용 확대는 HIV 시장 전체의 규모에 영향을 미칩니다. PrEP의 새로운 HIV 감염 예방 효과는 미래의 치료 시장 규모에 영향을 미칠 수 있습니다. 빅터루비를 생산하는 Gilead는 데코이와 같은 다른 약물로 PrEP 시장에서도 존재감을 보여주고 있으며, 치료와 예방에 더 일반적인 전략적 관심이 있음을 시사하고 있습니다. 새로운 장시간 작용 PrEP의 도입으로 상황이 더욱 바뀔 수 있습니다.
• 단일 정제 요법의 지속적인 이점 : 빅터루비와 같은 단독 요법은 단순하고 의약품 개선을 촉진하기 위해 대부분의 HIV 감염자에게 표준 치료법이 되었습니다. 1일 1정을 복용하는 것만으로 하는 간편함은 치료를 용이하게 해, 보다 양호한 결과를 가져옵니다. Victoralbi의 성공은 견고한 안전성 프로파일을 가진 소규모이지만 효과적인 STR이라는 입장에서 파생되었습니다. 이 추세는 STR이 시장에서 매우 큰 점유율을 유지한다는 것을 의미하지만, 앞으로 장시간 작용하는 신제품과의 경쟁이 예상됩니다.
• 특허 만료 및 제네릭 의약품의 경쟁에 의한 잠재적 영향 : 빅터루비는 현재 특허 보호하에 있지만, 특허가 만료되면 제네릭 의약품과의 경쟁이 가능합니다. 항레트로바이러스 약물의 제약은 치료비를 극적으로 줄일 수 있으며, 빅터루비와 같은 브랜드 의약품 시장 점유율과 수익에 영향을 미칠 수 있습니다. Gilead는 시장의 우위를 유지하기 위해 새롭고 혁신적인 HIV 치료제를 개발하고 이러한 미래 경쟁에 대비해야 합니다.

이러한 모든 새로운 동향은 빅터루비 시장을 재구성하기 위해 결합되었습니다. 빅터루비는 현재 단독 요법의 최상위 지위를 견지하고 있지만, 장시간 작용형 주사제의 이용 가능성이 높아지고, 병존 질환이 있는 환자의 치료가 중시되게 되어, 이에 대응해야 한다고 생각됩니다. PrEP의 성장은 전체 치료제 시장 규모에 영향을 미칠 수 있으며, 결국 제네릭 의약품 출시로 인해 가격 압력이 가해질 것으로 보입니다. Gilead의 혁신적인 능력과 치료 개발 능력은 이러한 시장 역학의 변화를 극복하고 HIV 치료 영역에서 흔들림없는 지위를 유지하는 열쇠가 될 것으로 보입니다.

빅터루비 시장의 최근 동향

빅터루비 시장을 둘러싼 현재의 사건은 HIV 치료의 첫 번째 선택 약물로서의 리더십을 확인하는 데 집중하고 있습니다. 이러한 사건에는 장기적인 효능 및 안전성 데이터의 도입, 공동 감염자 등 다양한 환자 집단에 대한 적용에 관한 연구, 환자의 편의성 및 치료 성적을 개선하기 위한 새로운 제제의 평가 등이 포함됩니다. 이들은 모두 빅터루비의 사용을 확대하고 새로운 HIV 치료의 전망에서 그 지위를 확인하는 것을 목표로합니다.

• 장기 효능 및 안전성 데이터 : 현재 진행 중인 임상 및 실제 임상시험은 빅터루비의 효능과 안전성에 대한 장기 데이터를 제공합니다. CROI(Conference on Retroviruses and Opportunistic Infections: 레트로바이러스와 기회감염에 관한 학회)를 포함한 주요 학회에서의 발표는 보통 빅타루비를 투여받은 환자에서 지속적인 바이러스 억제와 양호한 안전성 프로파일을 보여주는 다년간의 결과를 보여줍니다. 이것은 빅터루비가 장기적으로 안정된 치료 옵션임을 뒷받침합니다.
• 특정 환자 집단에서의 연구 : HIV 감염자의 특정 하위군에서 빅터루비의 효능과 안전성을 평가하기 위한 연구가 수행되었습니다. 여기에는 치료되지 않은 환자, 다른 항레트로바이러스 요법의 전환 환자, 노인, B형 간염 바이러스(HBV) 중복 감염과 같은 병존 질환이 있는 환자를 대상으로 한 연구가 포함됩니다. 이러한 연구에서 얻은 지식은 치료 지침이 되어 더 많은 환자군에게 빅터루비의 가치에 대한 지식을 전파하는 데 도움이 됩니다. 예를 들어, 빅터루비로 전환한 HIV 및 HBV 중복 감염 환자에서 높은 바이러스 억제율이 입증되었습니다.
• 새로운 제형 및 투여 방법 검토 : 빅터루비는 현재 1일 1회 투여의 경구 정제로서 판매되고 있지만, HIV 치료 분야 전체에서는 장시간 작용형 제제에 대한 연구가 활발히 이루어지고 있습니다. 단기적으로는 빅터루비에 특화된 것은 아니지만, 약물전달 시스템의 기술 진보에 의해 편의성 및 어드히어런스의 추가 향상을 목적으로 한, 빅터루비 또는 그 각 성분의 재제제가 장래에 개발될 가능성이 있습니다.
• 다른 항레트로바이러스 요법에 비해 상대적인 효능 및 안전성 연구 : 치료에서 빅터루비의 위치를 더욱 명확히 하기 위해 임상시험을 통해 널리 사용되는 다른 항레트로바이러스 요법 요법과 비교됩니다. 이러한 임상시험은 효능, 안전성, 내약성을 평가하여 임상의가 충분한 정보를 얻은 후 치료를 결정하는 데 도움이 됩니다. 이러한 상대적인 효능과 안전성 연구에서 얻은 좋은 결과는 빅터루비를 첫 번째 선택 약물로 권장합니다.
• 현실 증거 수집 대조 임상시험 이외에는 실제 임상 증거 수집 및 분석이 더욱 중요해지고 있습니다. 이 연구는 드문 프로토콜 조건 이외의 이종 환자군에서 비타루비의 효능과 내약성을 드러내어 실제 임상 조건 하에서 비타루비가 어떻게 작용하는지를 평가합니다. 실제 임상에서의 증거는 임상시험 정보를 보충하고 치료 권고에 추가로 기여하는 데 사용할 수 있습니다.

이러한 최근의 발전은 HIV 관리에서 빅터루비의 이용을 극대화하기 위한 지속적인 노력을 강조합니다. 장기 데이터 축적, 특수 집단 연구 및 HIV 치료 연구의 일반적인 동향은 모두 HIV와 함께 사는 개인의 삶을 향상시키기 위해 빅터 루비의 위상 및 유망성을 더 잘 이해하는 데 도움이 됩니다. 이러한 진보는 빅터루비가 현대 HIV 치료 시대에 필수적인 존재임을 더욱 증명합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경 및 분류
• 공급망

제3장 시장 동향 및 예측 분석

• 거시경제 동향 및 예측
• 업계의 촉진요인 및 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 빅터루비 시장 : 유형별

• 개요
• 유형별 매력 분석
• 선발 의약품 : 동향 및 예측(2019-2031년)
• 제네릭 의약품 : 동향 및 예측(2019-2031년)

제5장 세계의 빅터루비 시장 : 용도별

• 개요
• 용도별 매력 분석
• 병원 : 동향 및 예측(2019-2031년)
• 소매 약국 : 동향 및 예측(2019-2031년)
• 기타 : 동향 및 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별 세계의 빅터루비 시장

제7장 북미의 빅터루비 시장

• 개요
• 북미의 빅터루비 시장 : 유형별
• 북미의 빅터루비 시장 : 용도별
• 미국의 빅터루비 시장
• 멕시코의 빅터루비 시장
• 캐나다의 빅터 비마켓

제8장 유럽의 빅터루비 시장

• 개요
• 유럽의 빅터루비 시장 : 유형별
• 유럽의 빅터루비 시장 : 용도별
• 독일의 빅터루비 시장
• 프랑스의 빅터루비 시장
• 스페인의 빅터루비 시장
• 이탈리아의 빅터루비 시장
• 영국의 빅터루비 시장

제9장 아시아태평양의 빅터루비 시장

• 개요
• 아시아태평양의 빅터루비 시장 : 유형별
• 아시아태평양의 빅터루비 시장 : 용도별
• 일본의 빅터루비 시장
• 인도의 빅터루비 시장
• 중국의 빅터루비 시장
• 한국의 빅터루비 시장
• 인도네시아의 빅터루비 시장

제10장 기타 지역의 빅터루비 시장

• 개요
• 기타 지역의 빅터루비 시장 : 유형별
• 기타 지역의 빅터루비 시장 : 용도별
• 중동의 빅터루비 시장
• 남미의 빅터루비 시장
• 아프리카의 빅터루비 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회 및 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계의 빅터루비 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴 및 합작 사업

제13장 밸류체인에서 주요 기업의 기업 프로파일

• 경쟁 분석
• Gilead Sciences
• ABACUS MEDICINE
• Hetero Drugs
• Gador
• BMODESTO

제14장 부록

• List of Figures
• List of Tables
• Research Methodology
• Disclaimer
• Copyright
• Abbreviations and Technical Units
• About Us
• Contact Us

영문목차

The future of the global Biktarvy market looks promising with opportunities in the hospital and retail pharmacy markets. The global Biktarvy market is expected to grow with a CAGR of 2.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of HIV/AIDS, the growing awareness & screening programs, and the increasing preference for single-tablet regimens.

• Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Biktarvy Market

The Biktarvy market, as strong as it is, is not fixed. A number of very important trends are emerging that will shape its future direction and position within the overall HIV treatment environment. Some of these trends involve the creation and uptake of long-acting injectable treatments, the growing emphasis on the treatment of patients with comorbidities, the growing use of pre-exposure prophylaxis (PrEP), the continued relevance of single-tablet regimens, and the possible influence of patent losses and generic competition. Knowledge of these trends is essential to forecast future market trends.

• Long-Acting Injectable Therapies: Development and increasing use of long-acting injectable antiretroviral therapies, including cabotegravir and rilpivirine (Cabenuva), are a major trend in HIV therapy. These treatments bring the benefit of less frequent dosing (e.g., monthly or bi-monthly), which can simplify patient adherence and patient satisfaction by minimizing the pill burden. Whereas Biktarvy is a simple once-daily oral regimen, the attractiveness of even less-frequent dosing will appeal to some patients and could affect Biktarvy's market share over the long term.
• Increased Emphasis on Treating Patients with Comorbidities: Individuals with HIV are increasingly having comorbidities like cardiovascular disease, renal impairment, and bone health disorders. This requires HIV therapies that are not only efficacious in viral suppression but also safe and well-tolerated in the context of these other comorbidities. Long-term data on Biktarvy among older patients and those with comorbidities are being studied in ongoing research and clinical trials, which underscores the relevance of meeting these complicated patient requirements in the market.
• Pre-Exposure Prophylaxis Expansion: Although Biktarvy itself is not approved for PrEP, the increasing focus on HIV prevention regimens and the growth in PrEP use impact the size of the overall HIV market. The effectiveness of PrEP in preventing new HIV infections can, in turn, affect the size of the treatment market in the future. Gilead, the company that makes Biktarvy, also has a presence in the market for PrEP with other medications such as Decoy, suggesting a more general strategic interest in both treatment and prevention. The introduction of new, long-acting PrEP forms may further shift the scene.
• Ongoing Supremacy of Single-Tablet Regimens: Single-tablet regimens such as Biktarvy have become the standard of care for most individuals with HIV because they are simple and encourage improved adherence. The ease of taking only a single pill a day makes the treatment easier and can result in better outcomes. Biktarvy's success derives in part from its position as a small but effective STR that has a well-tolerated safety profile. This trend lines up with that STRs will maintain a very large share of the market though they will get competition from some new long-acting products on the horizon.
• Potential Effect of Patent Expirations and Generic Competition: Although Biktarvy is now under patent protection, the eventual lapse of these patents will allow generic competition. Generic forms of antiretroviral drugs can dramatically reduce the cost of treatment, potentially affecting the market share and revenue of branded medications such as Biktarvy. Gilead must be planning for this future competition by creating new and innovative HIV treatments in order to preserve its market dominance.

These new trends are all combined to reshape the Biktarvy market. Although Biktarvy's current status as a top single-tablet regimen is robust, it will have to adjust to the growing availability of long-acting injectables and the expanding emphasis on treating patients with comorbidities. The growth of PrEP may impact the total treatment market size, and the eventual launch of generics will bring pricing pressures. Gilead's innovative capacity and therapeutic development capabilities will be key in navigating these shifting market dynamics and keeping a solid footing in the HIV treatment space.

Recent Developments in the Biktarvy Market

Current events surrounding the Biktarvy market are focused on affirming its leadership as a first-line HIV treatment. These events include the introduction of long-term efficacy and safety data, studies of its application in varied patient populations such as those with co-infections, and evaluation of new formulations to improve patient convenience and outcomes. All these are aimed at expanding Biktarvy's use and affirming its place in the emerging HIV treatment landscape.

• Long-Term Efficacy and Safety Data: Ongoing clinical trials and real-world studies continue to generate long-term data on the efficacy and safety of Biktarvy. Presentations at key conferences, including the Conference on Retroviruses and Opportunistic Infections (CROI), typically include multi-year outcomes showing durable viral suppression and a good safety profile in patients receiving Biktarvy. This supports confidence in Biktarvy as a stable long-term treatment option.
• Studies in Specific Patient Populations: Research is being conducted to evaluate the effectiveness and safety of Biktarvy in specific subgroups of people living with HIV. This includes studies in treatment-naive individuals, those switching from other antiretroviral regimens, older adults, and individuals with comorbidities such as hepatitis B virus (HBV) co-infection. Findings from these studies assist in guiding treatment and broadening the knowledge of Biktarvy's value to a wider group of patients. For instance, high viral suppression rates have been demonstrated in patients with HIV/HBV co-infection switching to Biktarvy.
• Investigation of New Formulations and Delivery Options: Although Biktarvy is presently marketed as a once-daily oral tablet, there is active research across the overall HIV therapy space for long-acting formulations. Although nonspecific to Biktarvy in the short run, technology advances in drug delivery systems could in the future create reformulated versions of Biktarvy or its individual elements with the goal of further enhancing convenience and adherence.
• Relative Efficacy and Safety Studies Compared to Other Antiretroviral Regimens: Further to define its position in therapy, Biktarvy has been compared to other widely used regimens of antiretroviral therapy through clinical trials. Relative efficacy, safety, and tolerability are all evaluated in such studies, which serve to help clinicians make informed treatment decisions. Favorable results from these relative efficacy and safety studies endorse Biktarvy as a preferred first-line treatment.
• Collection of Real-World Evidence: Outside of controlled clinical trials, collection and analysis of real-world evidence are becoming more critical. These trials assess how Biktarvy works under real-world clinical practice conditions, revealing its efficacy and tolerability in a heterogeneous group of patients outside the rare protocol conditions of clinical trials. Real-world evidence can be used to supplement clinical trial information and contribute further to treatment recommendations.

These recent advances collectively emphasize the continued efforts to maximize the utilization of Biktarvy in HIV management. The accumulation of long-term data, research in special populations, and the general trends in HIV treatment research are all leading to a better understanding of Biktarvy's place and promise in enhancing the lives of individuals living with HIV. These advances serve to further establish Biktarvy as an integral part of the contemporary HIV treatment era.

Strategic Growth Opportunities in the Biktarvy Market

Strategic growth areas for Biktarvy are to build on its proven efficacy and safety profile to expand its use across various stages of HIV treatment. These areas are to consolidate its role in first-line treatment, emerge as the first choice among those switching treatment regimens, increase its use in patients with co-infections, and look into new formulations to make it more convenient for patients and improve adherence. Building on these areas can further enhance Biktarvy's market presence.

• Initial Therapy for Naive Patients: Biktarvy has already made a significant name for itself as an initial therapy for newly diagnosed HIV individuals. Its ability to provide fast and sustained viral suppression, combined with its tolerability profile and single-tablet once-daily regimen, makes it an appealing choice for initial therapy. Ongoing efforts towards educating healthcare professionals and newly diagnosed patients about these advantages can further establish its place in this critical use.
• Switch Therapy for Virologically Suppressed Patients: For patients who are already virologically suppressed on alternative antiretroviral regimens but perhaps having issues with tolerability, drug interactions, or pill burden, Biktarvy represents a streamlined and frequently better-tolerated option. Emphasizing Biktarvy as an exemplary switching option through clinical evidence illustrating superior outcomes or patient satisfaction can increase growth in this category.
• HIV/HBV Co-infected Individuals Treatment: HIV patients usually present with co-infections, and one such common co-infection is hepatitis B. Biktarvy's efficacy in suppressing both HIV and HBV has been shown in studies, which makes it an important choice for this particular patient group. Increased research and education among healthcare providers who treat co-infected patients can increase Biktarvy's application in this important use.
• Long-Acting Formulations Development: Although Biktarvy is already an oral tablet, the direction of long-acting injectable HIV treatments represents a future growth possibility. Gilead's knowledge in developing HIV drugs could be used to develop long-acting versions of Biktarvy or its active ingredients, providing improved convenience and adherence for those who want to take less medication more infrequently.
• Pediatric and Adolescent Use: Another opportunity for growth is extending the approved indication of Biktarvy to younger age groups, such as pediatric and adolescent patients. Clinical trials assessing the safety and efficacy of Biktarvy in these patient groups, with subsequent regulatory approvals, can extend its use and offer effective treatment to children and adolescents with HIV.

These strategic growth prospects, from establishing its place in first-line treatment to investigating new forms and broadening its application in certain patient populations, have the potential to greatly affect the Biktarvy market. By targeting these, Gilead is able to further build on the asset strengths of Biktarvy to meet the changing needs of individuals living with HIV while solidifying its leadership in the antiretroviral category.

Biktarvy Market Driver and Challenges

The trajectory of the Biktarvy market is defined by an intersection of drivers and challenges that result from technological advances in HIV therapy, economic determinants affecting drug pricing and availability, and the changing regulatory environment that defines pharmaceutical approvals and guidelines. These dynamics are essential for stakeholders to effectively navigate the market and for individuals living with HIV to obtain best-in-class care.

The factors responsible for driving the Biktarvy market include:

1. High Efficacy and Tolerability: Biktarvy's proven high viral suppression rates and good safety profile are key drivers of its commercial success. Clinical trial and real-world evidence all demonstrate its ability to suppress HIV with fewer side effects, and so it is a first choice for both treatment-naive patients and treatment-experienced patients. Its robust clinical profile favors its prescription by clinicians.

2. Convenient Once-Daily Single-Tablet Regimen: The ease of once-daily single-tablet therapy greatly enhances treatment adherence. For those with a chronic illness such as HIV, pill burden reduction makes their daily life easier and more likely to maintain regular medication, resulting in improved virologic response. This ease is one of the key reasons Biktarvy is so well received.

3. Strong Recommendation in Treatment Guidelines: Most HIV treatment guidelines globally recommend INSTI-based regimens, such as Biktarvy, as the first-line therapy of choice. These recommendations, supported by strong clinical evidence, lead to the use of Biktarvy by healthcare providers as a safe and effective first-line treatment for the majority of individuals with HIV.

4. Ongoing Innovation in HIV Treatment: Ongoing research and development in the HIV sector lend support to success stories of medications such as Biktarvy. Ongoing developments in antiretroviral drugs, aiming for increased efficacy, lower toxicity, and easier convenience, push the market toward newer and superior treatment alternatives. Biktarvy is one such development, aided by the advances in INSTI development.

5. Increased Awareness and Access to HIV Treatment: Global efforts to increase awareness of HIV, increase testing, and enhance access to treatment drive the expansion of the overall HIV drug market, including Biktarvy. As more individuals become diagnosed and connected to care, demand for effective antiretroviral therapies such as Biktarvy continues to increase.

Challenges in the Biktarvy market are:

1. Competition from Other Antiretroviral Therapies: The market for HIV treatment is competitive, with a number of other effective antiretroviral regimens, including other single-tablet regimens and new long-acting injectable therapies. This competition can restrict Biktarvy's market share and impose pricing pressures as manufacturers compete for patient preference and payer coverage.

2. Pricing and Reimbursement Concerns: The affordability of newer antiretroviral agents such as Biktarvy may be problematic, especially where there are constraints in resources or limited insurance cover. Favorable pricing and proper reimbursement policies that are strong must be negotiated so that market access is sustained and widespread use of Biktarvy is enabled.

3. Risk for Long-Term Side Effects and Resistance: Though Biktarvy has a benign safety profile, the risk of long-term side effects, including some that will not be easily recognized, cannot be eliminated. Moreover, despite the high resistance barrier of Biktarvy, drug resistance, which can evolve over time, is a possibility with any antiretroviral regimen, possibly curtailing its long-term efficacy in certain patients.

The Biktarvy market is fueled by its high efficacy, tolerability, convenient presentation, and favorable positioning in treatment guidelines, within a backdrop of continuous innovation and expanding access to HIV care. But it has challenges posed by competition, price and reimbursement complexities, and long-term side effects or resistance risks. Managing these drivers and challenges will be essential for Biktarvy in order to preserve its market leadership and remain an essential part of HIV treatment.

List of Biktarvy Companies

• Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, Biktarvy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Biktarvy companies profiled in this report include:
• Gilead Sciences
• ABACUS MEDICINE
• Hetero Drugs
• Gador
• BMODESTO

Biktarvy Market by Segment

The study includes a forecast for the global Biktarvy market by type, application, and region.

Biktarvy Market by Type [Value from 2019 to 2031]:

• Brand Drugs
• Generic Drugs

Biktarvy Market by Application [Value from 2019 to 2031]:

• Hospitals
• Retail Pharmacy
• Others

Biktarvy Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biktarvy Market

The Biktarvy market, a major HIV treatment segment worldwide, keeps growing in major geographies. Trends are influenced by drivers like growing adoption rates, competition from established and emerging antiretroviral therapies, pricing trends, and regulatory regimes. Gilead Sciences' Biktarvy, a once-daily, single-tablet regimen, has become a popular treatment because of its efficacy, safety profile, and convenience. Yet, market conditions differ significantly between countries, shaped by local healthcare systems, economic conditions, and HIV prevalence. It is important for stakeholders in the pharmaceutical sector and people living with HIV to understand these regional differences.

• United States: Biktarvy enjoys robust market leadership in the US, fueled by strong demand and favorable reimbursement. Sales continue to increase, with a 7% year-on-year increase seen in the first quarter of 2025, contributing largely to Gilead's overall revenues. Although long-acting injectables such as Cabenuva represent competitive pressure, Biktarvy's established track record of efficacy and the convenience of a once-daily oral regimen guarantee its continued solid standing. Recent price revisions have taken place, demonstrating a balance between revenue generation and market access for Gilead.
• China: Data on recent developments specifically for Biktarvy in China are sparse in the available search results. The overall Chinese pharmaceutical market, though, is seeing growth in traditional and specialty pharmaceuticals. Single-tablet regimens are becoming the norm for HIV, with branded therapies such as Biktarvy gaining strong share in the HIV segment. The overall pharmaceutical trend suggests a growing market for innovative treatments, which could positively impact Biktarvy's future trajectory in the region.
• Germany: There are no specific recent developments on Biktarvy in Germany set out in the search results given. Nevertheless, Germany is a major market across Europe, and trends in other large European markets, including attention to single-tablet regimens and the effect of pricing and reimbursement policy, are likely applicable. The general European market will experience competitive prices as a result of policy action, which might influence the market dynamics of Biktarvy in Germany.
• India: The search results do not yield particular recent updates on Biktarvy in India. The Indian pharma industry is, however, interested in bolstering its infrastructure to be a world leader. The overall antiviral drug market is growing, led by the rise in viral disease prevalence. As much as Biktarvy is an important global product, its particular market trends in India would be determined by local prices, access initiatives, and the availability of generic antiretrovirals.
• Japan: Recent data suggest that Biktarvy is approved and on the market in Japan. This evidence has been presented at international meetings by Gilead, highlighting the safety and efficacy of Biktarvy across a range of patient subgroups. Japan, as with other developed countries, would prefer effective, convenient HIV treatment, which would play in the favor of Biktarvy. Market conditions would be shaped by the healthcare system and regulation in Japan.

Features of the Global Biktarvy Market

• Market Size Estimates: Biktarvy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Biktarvy market size by type, application, and region in terms of value ($B).
• Regional Analysis: Biktarvy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the Biktarvy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Biktarvy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Biktarvy market by type (brand drugs and generic drugs), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Biktarvy Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Brand Drugs: Trends and Forecast (2019-2031)
• 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Biktarvy Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Retail Pharmacy: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Biktarvy Market by Region

7. North American Biktarvy Market

• 7.1 Overview
• 7.2 North American Biktarvy Market by Type
• 7.3 North American Biktarvy Market by Application
• 7.4 United States Biktarvy Market
• 7.5 Mexican Biktarvy Market
• 7.6 Canadian Biktarvy Market

8. European Biktarvy Market

• 8.1 Overview
• 8.2 European Biktarvy Market by Type
• 8.3 European Biktarvy Market by Application
• 8.4 German Biktarvy Market
• 8.5 French Biktarvy Market
• 8.6 Spanish Biktarvy Market
• 8.7 Italian Biktarvy Market
• 8.8 United Kingdom Biktarvy Market

9. APAC Biktarvy Market

• 9.1 Overview
• 9.2 APAC Biktarvy Market by Type
• 9.3 APAC Biktarvy Market by Application
• 9.4 Japanese Biktarvy Market
• 9.5 Indian Biktarvy Market
• 9.6 Chinese Biktarvy Market
• 9.7 South Korean Biktarvy Market
• 9.8 Indonesian Biktarvy Market

10. ROW Biktarvy Market

• 10.1 Overview
• 10.2 ROW Biktarvy Market by Type
• 10.3 ROW Biktarvy Market by Application
• 10.4 Middle Eastern Biktarvy Market
• 10.5 South American Biktarvy Market
• 10.6 African Biktarvy Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Biktarvy Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Gilead Sciences
  • Company Overview
  • Biktarvy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 ABACUS MEDICINE
  • Company Overview
  • Biktarvy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Hetero Drugs
  • Company Overview
  • Biktarvy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Gador
  • Company Overview
  • Biktarvy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 BMODESTO
  • Company Overview
  • Biktarvy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us